We are live on ! Find out more
NRSN icon

NeuroSense Therapeutics
NRSN

13 hedge funds and large institutions have $776K invested in NeuroSense Therapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

171% more capital invested

Capital invested by funds: $286K → $776K (+$490K)

86% more funds holding

Funds holding: 7 → 13 (+6)

1.64% more ownership

Funds ownership: 1.16% → 2.8% (+1.6%)

Holders
13
Holders Change
+6
Holders Change %
+85.71%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$253K
2
Morgan Stanley
Morgan Stanley
New York
+$118K
3
Jane Street
Jane Street
New York
+$74.3K
4
HF
HRT Financial
New York
+$74.1K
5
SWP
Stratos Wealth Partners
Ohio
+$23K

Top Sellers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
-$101K
2
XT
XTX Topco
Cayman Islands
-$4.71K

NRSN Hedge Fund Activity: Q4 2024 in Review

13 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q4 2024, worth a combined $776K — up 171% from $286K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new NRSN positions and 1 closed out — a net gain of 6 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $253K. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $101K sold.

  • 13 institutional investors held NeuroSense Therapeutics (NRSN) as of Q4 2024, up from 7 in Q3 2024.
  • Funds reported $776K of NeuroSense Therapeutics stock for Q4 2024, up 171% quarter-over-quarter.
  • 7 funds opened new NeuroSense Therapeutics positions in Q4 2024 and 1 closed out, a net change of +6 holders.
  • The largest NeuroSense Therapeutics buyer in Q4 2024 was Citadel Advisors, an estimated $253K added.
  • The largest NeuroSense Therapeutics seller in Q4 2024 was Cantor Fitzgerald, an estimated $101K sold.

Based on aggregated 13F filings for Q4 2024.